1. Pink Sheet
  2. >>Product Reviews

GSK Malaria Vaccine Gets Landmark Clearance For Use In Africa

WHO Recommendation Takes Account Of 2015 EMA Scientific Opinion

 
• By Ian Schofield

Mosquirix is set for much wider availability in sub-Saharan Africa thanks to positive results from a pilot program in Ghana, Kenya and Malawi. The next step is deciding how to fund the vaccine’s rollout over the coming years.

Mosquito drinks blood from a person
More than 260,000 African children under five die from malaria each year • Source: Alamy

GlaxoSmithKline’s malaria vaccine Mosquirix (RTS,S), which has just been cleared for wider distribution in Africa by the World Health Organization, is the latest product to be approved for use based on a scientific opinion from the European Medicines Agency under a special procedure for medicines destined for non-EU markets.

On 6 October, the WHO said it was recommending widespread use of the vaccine for children in sub-Saharan Africa and other regions with moderate to high Plasmodium falciparum malaria transmission

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Product Reviews

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 
• By Sue Sutter and Bridget Silverman

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.